Vera Therapeutics, Inc. (VERA) saw its stock soar 5.08% in intraday trading on Thursday, driven by a series of analyst updates and the company's announcement of its participation in an upcoming healthcare conference.
Wedbush adjusted its price target on Vera Therapeutics' stock from $38 to $34 while maintaining a Neutral rating. Additionally, other analysts provided insights and ratings on the company, potentially influencing investor sentiment.
Furthermore, Vera Therapeutics announced that its management team will participate in a fireside chat and one-on-one investor meetings at the TD Cowen 45th Annual Health Care Conference, scheduled for March 3-5, 2025. This upcoming event presentation may have generated interest among investors and contributed to the stock's upward movement.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.